AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC 50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma.
性状
Solid
IC50 & Target[1][2]
IC50: 0.28 nM (LTC4S).
体内研究(In Vivo)
AZD9898 with the single dose of 100 mg/kg is well tolerated and no safety concerns are raised. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Rat 6M/group.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Munck Af Rosensch?ld M, et al. Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for